Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) shares saw unusually-high trading volume on Thursday . Approximately 3,168,658 shares traded hands during mid-day trading, an increase of 172% from the previous session’s volume of 1,166,336 shares.The stock last traded at $15.17 and had previously closed at $14.64.
Analyst Ratings Changes
Several analysts have recently commented on the stock. Wall Street Zen raised shares of Janux Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, April 5th. Truist Financial reissued a “buy” rating and set a $26.00 target price (down from $80.00) on shares of Janux Therapeutics in a research note on Thursday. Weiss Ratings upgraded shares of Janux Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, April 22nd. JonesTrading decreased their price target on shares of Janux Therapeutics from $50.00 to $28.00 and set a “buy” rating for the company in a research note on Tuesday, April 28th. Finally, Wedbush dropped their price objective on shares of Janux Therapeutics from $45.00 to $36.00 and set an “outperform” rating on the stock in a report on Friday, May 8th. Ten equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Janux Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $40.15.
Get Our Latest Stock Analysis on JANX
Janux Therapeutics Price Performance
Janux Therapeutics (NASDAQ:JANX – Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.13. The business had revenue of $3.73 million during the quarter, compared to analyst estimates of $4.36 million. Equities research analysts predict that Janux Therapeutics, Inc. will post -1.7 earnings per share for the current fiscal year.
Insider Activity at Janux Therapeutics
In related news, VP Maria Dobek sold 2,038 shares of Janux Therapeutics stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $14.17, for a total transaction of $28,878.46. Following the transaction, the vice president owned 32,270 shares of the company’s stock, valued at $457,265.90. The trade was a 5.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Janeen Noel Doyle sold 4,059 shares of the company’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $14.03, for a total value of $56,947.77. Following the sale, the insider owned 75,941 shares of the company’s stock, valued at $1,065,452.23. This trade represents a 5.07% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 7.90% of the company’s stock.
Hedge Funds Weigh In On Janux Therapeutics
Several large investors have recently bought and sold shares of JANX. Nano Cap New Millennium Growth Fund L P bought a new stake in shares of Janux Therapeutics in the 4th quarter worth $34,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Janux Therapeutics in the fourth quarter valued at about $51,000. Osaic Holdings Inc. lifted its position in shares of Janux Therapeutics by 704.6% during the second quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock valued at $80,000 after purchasing an additional 3,037 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Janux Therapeutics by 175.5% during the second quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock valued at $91,000 after purchasing an additional 2,502 shares in the last quarter. Finally, Winthrop Capital Management LLC purchased a new position in Janux Therapeutics during the third quarter worth about $106,000. 75.39% of the stock is currently owned by institutional investors.
About Janux Therapeutics
Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.
Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.
Read More
- Five stocks we like better than Janux Therapeutics
- 3 ETFs Pairing Market-Beating Returns With High Dividend Yields
- MarketBeat Week in Review – 06/22 – 06/26
- Rocket Lab’s NASA Win Tests Key Support After Sharp Pullback
- AST SpaceMobile Just Nailed a Major Launch—So Why Is the Stock Crashing?
Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
